Table 2

Changes in renal function with SGLT2 inhibitors (refs. 4547)

PlaceboCanagliflozin (mg)PlaceboDapagliflozin (mg)PlaceboEmpagliflozin (mg)
1003005101025
n909089848385879089
eGFR (mL/min/1.73 m2)
Baseline40.039.838.845.644.243.9CKD2 71.8CKD2 70.8CKD2 72.3
CKD3 44.3NACKD3 45.4
CKD4 22.0NACKD4 24.4
Change from baseline to 6 months−1.4−3.6−3.9−0.25−2.38−4.80NANANA
Change from baseline to 1 yearNANANA−2.58−2.08−4.46CKD2 −0.71CKD2 −2.04CKD2 −2.47
CKD3 −0.3CKD3 −2.8
CKD4 −1.1CKD4 −1.4
Change from baseline to 2 yearsNANANA−2.38−1.71−3.50NANANA